Altan Pharma
Altan Pharma is a specialty pharmaceutical company and subsidiary of Ethypharm Group that develops, manufactures, and markets injectable medicines for hospital use, focusing on CNS conditions including severe pain management and addiction treatment across European markets.
- Company typePrivate
- Founded2015
- HeadquartersDún Laoghaire, Ireland
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Altan Pharma does
Altan Pharma (Altan Pharmaceuticals, S.A.) is a specialty pharmaceutical company that develops, manufactures, and markets injectable medicines for hospital use, with a focus on Central Nervous System (CNS) conditions including severe pain management and addiction treatment. The company's core product portfolio includes Recivit (fentanyl-based treatment for intense pain), Nefopam 20 mg/2 ml injectable solution (an analgesic for moderate to severe pain), and a range of CNS medications and hospital injectables. Altan Pharma operates as a wholly-owned subsidiary of Ethypharm Group, a European specialty pharmaceutical company with operations across Spain, France, Germany, the United Kingdom, and China.
The company's business model is built on B2B pharmaceutical distribution to hospitals and healthcare providers through established pharmaceutical wholesale networks, primarily within Spain. Altan Pharma expands its product portfolio through licensing agreements with partners such as Medochemie (for Nefopam in Spain) and leverages Ethypharm Group's pan-European infrastructure for geographic reach. The company is currently investing in production capacity expansion in Spain, supported by EU FEDER regional incentive funding. Revenue mechanics are not publicly disclosed, but the company generates income through product sales of specialty injectable medicines in the hospital channel. The company's go-to-market relies on direct sales to institutional healthcare buyers and licensing partnerships to broaden therapeutic coverage in pain management and addiction treatment.
Altan Pharma maintains a focused differentiation strategy centered on domain specialization in CNS and hospital injectable therapeutics - areas with high regulatory barriers and limited competition. The company actively pursues business development partnerships to address unmet medical needs in severe pain management, and its parent Ethypharm Group positions the entity for continued portfolio expansion through licensing and geographic extension across European markets.
Altan Pharma firmographics
Firmographics- Name
- Altan Pharma
- Legal name
- Altan Pharmaceuticals, S.A.
- Website
- https://altanpharma.eu
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Altan Pharma is a specialty pharmaceutical company and subsidiary of Ethypharm Group that develops, manufactures, and markets injectable medicines for hospital use, focusing on CNS conditions including severe pain management and addiction treatment across European markets.
- Ownership category
- akta.pro rank
Altan Pharma industry classification
Industry- Product category
- Specialty Injectable Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Altan Pharma is headquartered
LocationHeadquarters
- HQ city
- Dún Laoghaire
- HQ country
- Ireland
- HQ region
- Europe
Offices1 record
Markets served
Altan Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
Distribution channels1 record
Marketing channels1 record
Altan Pharma product offering
Product offeringCore offering
Altan Pharma develops, manufactures, and markets specialty injectable pharmaceutical medicines focused on Central Nervous System (CNS) conditions and hospital injectables. The portfolio addresses severe pain management and addiction, including fentanyl-based treatments (Recivit) and analgesic injectable solutions (Nefopam 20 mg/2 ml). The company operates as part of the Ethypharm Group, commercializing products primarily in Spain and broader European markets through licensing agreements and pharmaceutical distribution networks.
Product overview
Altan Pharma (Altan Pharmaceuticals, S.A.) is a company within the Ethypharm Group, a European pharmaceutical company specializing in Central Nervous System (CNS) conditions and Hospital Injectables. Products include treatments for severe pain and addiction. The company operates within the broader Ethypharm portfolio, which also commercializes products like Recivit (fentanyl) for intense pain and Nefopam injectable solutions through regional partnerships.
Differentiator
Problem solved
Functional benefit
Companies that use Altan Pharma
Customer profileSegments2 records
Ideal customer profiles1 record
Altan Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Altan Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- MedochemiecoreEthypharm Iberia signed a licensing agreement with Medochemie to commercialize Nefopam 20 mg/2 ml injectable solution in Spain. This analgesic provides effective treatment for moderate to severe pain, addressing real needs for new therapeutic options in the Spanish market. This agreement supports Ethypharm's ambition to expand its portfolio of essential medicines.
Recent moves6 records
Expansion highlights4 records
Altan Pharma competitors and assessment
Company assessmentDirect peers
- Grünenthal: European specialty pharma company focused on pain management. Previously distributed Recivit in France before it returned to Ethypharm's portfolio in April 2025, making it a directly comparable specialty pain player competing for the same therapeutic area and customer base.
- Medochemie: Cyprus-based global generic and specialty pharmaceutical manufacturer that signed the licensing agreement with Ethypharm Iberia for Nefopam injectable in Spain. Directly comparable as a producer of injectable finished dosage forms targeting similar hospital customers.
- Mallinckrodt Pharmaceuticals: Specialty pharmaceutical company with a portfolio in hospital injectables, pain management, and addiction therapies. Comparable in therapeutic focus (CNS, severe pain) and in delivering injectable specialty products to hospital channels.
- Indivior: Specialty pharmaceutical company focused on addiction treatment and CNS disorders. Directly comparable as a CNS-focused player addressing the same addiction-therapy use case that Altan serves alongside severe pain.
- Hameln Pharmaceuticals: European specialty manufacturer of hospital injectable medicines, part of the Aenova Group. Closely aligned with Altan's hospital-injectables focus, serving similar hospital pharmacy and clinical customers with finished injectable preparations.
- Hikma Pharmaceuticals: Global specialty pharmaceutical company with a substantial injectable generics business serving hospital customers. Comparable as a manufacturer of injectable finished dosage forms across European and global markets, with similar GTM into hospital channels.
- Recipharm: European pharmaceutical contract development and manufacturing organization with strong sterile injectable capabilities. Comparable as a European-based producer of injectable pharmaceutical preparations serving hospital and specialty pharma customers.
Emerging players
- Camurus: Swedish specialty pharmaceutical company developing CNS therapies using advanced drug delivery. Comparable as a CNS-focused specialty pharma peer, though more research-stage and narrower in indications than Altan's hospital-injectables franchise.
Broad incumbents
- B. Braun: Global medical technology and pharmaceutical company supplying hospital injectable solutions, infusion therapy, and related products. A broader incumbent that overlaps with Altan in hospital injectable supply, though across a much wider product portfolio.
Others
- Ethypharm Group: Parent group of Altan Pharma and itself a European specialty pharma in CNS and hospital injectables. Relevant as the controlling parent whose strategic direction and capital allocation shape Altan's opportunity set and as a direct reference point for size and scope.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Altan Pharma social profiles
Digital presenceAltan Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Altan Pharma leadership team
Management profileNumber of profiles
Altan Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Altan Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Altan Pharma
What does Altan Pharma do?
Altan Pharma develops, manufactures, and markets specialty injectable pharmaceutical medicines focused on Central Nervous System (CNS) conditions and hospital injectables. The portfolio addresses severe pain management and addiction, including fentanyl-based treatments (Recivit) and analgesic injectable solutions (Nefopam 20 mg/2 ml). The company operates as part of the Ethypharm Group, commercializing products primarily in Spain and broader European markets through licensing agreements and pharmaceutical distribution networks.
Is Altan Pharma a public or private company?
Altan Pharma is a private company. It is classified as corporate owned and is currently operating.
When was Altan Pharma founded?
Altan Pharma was founded in 2015. It employs 251 to 500 people.
Where is Altan Pharma based?
Altan Pharma is headquartered in Dún Laoghaire, Ireland, in the Europe region.
Who are Altan Pharma's main competitors?
Direct peers on record are Grünenthal, Medochemie, Mallinckrodt Pharmaceuticals, Indivior, Hameln Pharmaceuticals, Hikma Pharmaceuticals and Recipharm. Camurus is listed as an emerging player. B. Braun is listed as a broad incumbent. Ethypharm Group is listed as an others.
Does Altan Pharma have an API?
No public API is recorded for Altan Pharma.
What industry is Altan Pharma in?
Altan Pharma's product category is Specialty Injectable Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.